Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBAvalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial (NCT06329401) is expected to enroll 300 progressive PF patients, who will receive either one of….
New prototype therapy may repair IPF lung scarring by …
WEBby Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. Immune cells separate IPF, fibrotic hypersensitivity pneumonitis September 6, 2024; Tales of 2 women, both named Melissa, on their IPF journeys September 3, 2024; Patient journeys highlighted for this year’s PF Awareness Month August 30, 2024 ‘You can’t have that’: The diet restrictions since my transplant August 27, 2024; Phase 1b trial launched of inhaled nintedanib for ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
Oral BMS-986278 slows lung decline in progressive PF, Phase 2...
WEBSep 25, 2023 · These findings are consistent with previously reported data from a group of idiopathic pulmonary fibrosis (IPF) patients also participating in the clinical trial, whose lung function decline decreased by 62% with treatment at that dose.. Study results support moving BMS-986278 into global Phase 3 testing in a trial program being called ALOFT, according to the therapy’s developer, Bristol ...
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
WEBOct 28, 2022 · by Steve Bryson, PhD October 28, 2022. Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also ...
New Targeted Therapies May Ease Pulmonary Fibrosis, Studies Find
WEBNov 16, 2020 · In the second study, the investigators looked for ways to reduce pro-fibrosis macrophage activity. Titled “ Reprogramming of profibrotic macrophages for treatment of bleomycin‐induced pulmonary fibrosis, ” that study was published in the journal EMBO Molecular Medicine. Previous research had indicated that activating the protein toll‐like receptor 7 (TLR7) could reduce the fibrotic ...
Ifetroban cleared to be tested in IPF patients in Phase 2 clinical ...
WEBJun 2, 2023 · The announcement follows the U.S. Food and Drug Administration (FDA) clearance of the company’s investigational new drug (IND) application — a formal request companies submit to regulatory agencies asking permission to start testing an investigational therapy in human trials.
Phase 3 INOpulse Trial Enrolls First Patient at Risk of...
WEBDec 4, 2020 · Top-line data from the trial, called REBUILD (NCT03267108), are expected by 2022.“We are pleased to have enrolled the first patient in our Phase 3 REBUILD study, as it marks an important milestone in our efforts to develop the first potential therapy to treat a broad [PF] population that includes patients at risk of pulmonary hypertension,” Fabian Tenenbaum, CEO of Bellerophon, said in a ...
Skip to content